Kitov Pharmaceuticals announced that it has appointed Dr. Gil Ben-Menachem as Vice President Business Development. The appointment comes following Kitov's recent announcement that the pivotal Phase III trial of its lead drug candidate KIT-302 successfully met its primary endpoint. Dr. Ben-Menachem is a seasoned executive with over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries.

He was most recently Head of Innovative Products at Dexcel Pharma.